Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05098704 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

Study acronym: PSSIT
StatusRecruiting
PhasePhase 2/3
Started2022-06-22
View on ClinicalTrials.gov ↗

Amendment history

2026-07-03
Study Identification, Study Status, Contacts/Locations v7
Primary completion date2031-06→2032-06
Completion date2031-06→2032-06
Study sites10→11
2025-07-11
Study Status, Contacts/Locations v6
Primary completion date2030-06→2031-06
Completion date2030-06→2031-06
Study sites9→10
2024-11-07
Study Status, Contacts/Locations v5
Study sites8→9
2024-05-31
Study Status v4
Primary completion date2029-06→2030-06
Completion date2029-06→2030-06
2024-01-18
Study Status, Contacts/Locations v3
Study sites9→8
Show 2 earlier versions
2022-10-17
Study Status, Eligibility, Contacts/Locations v2
Study sites7→9
Eligibility criteria+128 characters
[...] specificity: anti-Scl70 or anti-centromere or anti-RNApolIII., or any other auto-antibodies related to systemic sclerosis Patient with RP reported by the subject and confirmed by th [...] l. Patient treated by immunosuppressive agent at screening. Patient treated by anticoagulants at screening Pregnant or breastfeeding women. Women of childbearing age refusing effective contraception method during the study treatment (24 months). Incompetent adults (i.e. Individuals under the protection of a conservator)
2022-06-24
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2029-01→2029-06
Completion date2029-01→2029-06
Start dateestimated 2022-01→confirmed 2022-06-22
Study sitesdetails revised at 7 of 7 sites
2021-10-15
Original filing
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.
Trial Details
NCT Number NCT05098704
Lead Sponsor University Hospital, Bordeaux
Collaborators: Ministry for Health and Solidarity, France
Conditions Scleroderma, Systemic Sclerosis
Enrollment 90 participants
Start Date 2022-06-22
Primary Completion 2032-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-07